Solstice Oncology secures $225m to drive porustobart’s development for cancer
The funding round was led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors.
Drug Development
TwoStep Therapeutics raises $62.5m in funding to advance TS-104
Gilead launches research facility in US for new medicine development
FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia
LSTM opens $23m robotic AI lab for infection research
Novartis India acquires Pfizer brands for $132m
AtomVie opens $160m radiopharmaceutical manufacturing facility in Ontario
FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer
